Navigation Links
Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Date:10/22/2007

stent design and a reduction in strut thickness may contribute to improved clinical outcomes for TAXUS Liberte in these difficult and challenging lesions."

"Results from the TAXUS ATLAS studies demonstrate the successful transfer of Boston Scientific's leading paclitaxel technology to our next-generation TAXUS Liberte Stent," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "Improved clinical outcomes and positive data on deliverability in complex lesions are a powerful demonstration of the continued leadership of Boston Scientific and our TAXUS Stent platform. TAXUS Liberte is the preferred drug-eluting stent in virtually every country where it is sold, and we look forward to bringing this technology to the U.S. in 2008."

The TAXUS ATLAS Small Vessel and Long Lesion studies are global, multi- center, historically controlled trials investigating de novo lesions in 411 patients at 24 sites. The Small Vessel study was designed to evaluate the safety and efficacy of the TAXUS Liberte 2.25 mm Stent for superiority compared to a case-matched historical bare-metal stent (BMS) control (Express Stent), and non-inferiority against a case-matched historical control of TAXUS Express Stent patients. The Long Lesion study was designed to demonstrate that the TAXUS Liberte Long (38 mm) Stent is non-inferior in safety and efficacy compared to a case-matched historical control of TAXUS Express Stent patients.

The Small Vessel study met its primary superiority endpoint compared to the BMS group (45.6% vs. 32.1% diameter stenosis, p<0.0001) and non- inferiority compared to the TAXUS Express group (38.4% vs. 32.1% diameter stenosis, p=0.0351). The TAXUS Liberte 2.25 mm Stent showed significant statistical reduction in target lesion revascularization (TLR) at nine months with a rate of 5.8% as compared to 13.7% in the TAXUS Express Stent (p=0.024), resulting in a 58% relative reduction. Overall target vessel revascularization (TVR) was 10.1% for th
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
4. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
5. To Stent or Not: Is That the Question?
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
9. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
11. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. today ... financing. Led by Sears Capital Management and Biobrit LLC, ... Zakrzewski , the $1.5 million financing positions SiteOne to ... pain and to further develop its technology platform for ... In conjunction with the financing, Lowell ...
(Date:9/23/2014)... According to the new ... Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & ... Forecasts to 2019", published by MarketsandMarkets, studies the global ... 2014 to 2019. The market is expected to ... 9.6% from 2014 to 2019. Browse ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... 2010 Diopsys, Inc. today announced the development of ... (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing ... SD-OCT is an imaging technique used to ... Nerve Fiber Layer (RNFL) which can help them diagnose ...
... 20, 2010 A small Midwest college that is producing ... a $35 million grant from Lilly Endowment to launch a ... northern Indiana, has a Nobel Laureate in chemistry, the inventor ... and the first female commissioner of the U.S. Food and ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 AmerisourceBergen’s ... Canadian specialty market, is now providing U.S. manufacturers ... new 160,000-square-foot distribution center coupled with its fully-licensed ... healthcare industry has historically been difficult for smaller ... government regulation complexities. As a result of these ...
(Date:9/23/2014)... 23, 2014 The print component of ... Metro, with a circulation of approximately 327,720 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with Michael Landsberg, host of TSN’s Off ...
(Date:9/23/2014)... WASHINGTON, Sept. 23, 2014 Antibiotics revolutionized health ... bacteria that once killed thousands of people. But ... strains of antibiotic-resistant bacteria are popping up more ... the current shortage of new antibiotics and discusses ... answers the question: Why should you finish your ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 On September ... by Keith Simmons for an episode. Simmons is the founder ... Deierlein believed the audience would like to know. At the ... get the idea to start this magazine?” Simmons replied by ... advertising sales person. In 2005, I quit that and decided ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... scientists have been chosen from a highly competitive field ... Merck Sharp & Dohme and Advance to boost the ... Antisense Therapeutics Ltd (ASX code: ANP) Research Director Dr ... have been selected as joint winners of the 2008 ...
... important international relationships is top of the agenda ... Dr Raisa Monteiro, when she meets with leading ... One of two Australian life scientists chosen from ... prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro ...
... anemia in expectant mothers and spinal birth defects in newborns, the ... has now been shown to blunt the damaging effects of heart ... In a new study, an international team of heart experts at ... daily of folate, also known as folic acid or vitamin B9, ...
... Solution for ... Employers, ... believe the future of managing health care costs lies in,helping their ... Seventh Annual Tri-State Area Employee,Benefit Survey., Cowden Associates, the region,s ...
... US$1.75 million of new available funds -, ... Inc. (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, ... under the agreement to repay US$1.75 million of ... Laurus Master Funds),in common shares., The conversion ...
... ROLLA, Mo., March 27 While today,s shaky economy ... has been an,exception. In fact, there is currently a ... positions. Furthermore, according to the latest,projections from the U.S. ... replacement nurses will be needed by 2014 -- and ...
Cached Medicine News:Health News:Rising Australian biotech stars set to connect on the world stage 2Health News:DendriMed scientist seeks to fast-track success 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 3Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 4Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 2Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 3Health News:Bioniche Converts a Portion of its Debt to Equity 2Health News:NurseAuction.com Aims to Alleviate Nurse Shortage with Online Nurse Bidding 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: